Document:

EX-10.1

 Exhibit 10.1 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 240.24b-2 

Material Transfer and Exclusivity Agreement 

This Material Transfer and Exclusivity Agreement (“Agreement”), effective as of February 17th, 2014 (the
“Effective Date”), is entered into between LES LABORATOIRES SERVIER having offices at 50, rue Carnot, 92284 Suresnes, France, registered with the Nanterre Commercial Registry under number 085 480 796 (“LLS”) and,
acting jointly and severally with LLS, INSTITUT DE RECHERCHES SERVIER, having offices at 3 rue de la République, 92150 Suresnes, France, registered with the Nanterre Commercial Registry under number 778 150 326 (“IDRS”), (LLS
and IDRS are hereinafter collectively referred to as “Servier”) and CELLADON CORPORATION, having offices at 12760 High Bluff Drive Suite 240 San Diego, CA 92130, USA (“Celladon”) and confirms the terms upon which
Celladon will provide the following Celladon proprietary compounds: CDN[...***...], CDN[...***...] and CDN[...***...] (CDN[...***...], CDN[...***...] and CDN[...***...] are collectively referred to as the “Celladon Compounds”), and
certain information related thereto to Servier for the purpose of enabling Servier to conduct the evaluation of the Celladon Compounds as outlined in Attachment 1 attached hereto (the “Evaluation”) in order for Servier to evaluate
its interest in a possible business arrangement with Celladon for the study of SERCA activators in the treatment of type 2 Diabetes (the “Purpose”). Servier and Celladon agree as follows: 

 

	1.	Delivery and Procedure. Within ten (10) days of the Effective Date, Celladon shall, at no charge to Servier, deliver to Servier or its designee at 11, rue des Moullneaux 92150 Suresnes, France, samples of
the Celladon Compounds (the “Materials”) in the quantities specified in Attachment 1. If Servier determines in good faith that such quantities of the Materials are not sufficient for Servier to perform the Evaluation pursuant to
Attachment 1, Celladon shall, upon request of Servier and subject to availability, promptly deliver to Servier or its designee any additional quantities of the Materials as Servier may reasonably require to perform the Evaluation. 

 

	2.	License Grant; Subcontracting. Subject to the terms and conditions of this Agreement, Celladon hereby grants to Servier a non-exclusive, non-sublicensable, royalty free license solely to use the Materials for the
Evaluation during the Evaluation Period. It is understood and agreed that Servier may subcontract the conduct of the Evaluation to Servier’s Affiliates (entities at least 50% owned by, under common ownership with, or which own at least 50% of,
Servier) and Servier’s subcontractors, including CEREP; provided, however, that each such Affiliate and subcontractor is bound by written agreement: (a) to retain and use the Materials in compliance with this Agreement; (b) to
assign all right, title and interest in and to all Compound Inventions and Results (defined below) to Servier so that Servier may comply with its obligations under Paragraph 8 hereof; and (c) to obligations of confidentiality no less stringent
than those set forth in this Agreement; and provided, further, that Servier shall be responsible for the compliance of each such Affiliate and subcontractor with this Agreement, and any breach of this Agreement by any such Affiliate or
subcontractor shall be deemed a breach of this Agreement by Servier. 

  

	3.	Service and Instruction. Prior to or concurrent with the delivery of the Materials to Servier, Celladon shall provide, at no charge to Servier, available information necessary or useful to Servier in performing
the Evaluation. All information disclosed by Celladon to Servier under this Paragraph 3 shall be subject to the provisions of Paragraph 9. 

  

	4.	Evaluation Period; Term. The Evaluation shall commence when Servier receives the initial quantities of the Materials specified in Attachment 1 and related information from Celladon, and shall continue for a
period of six (6) months (the “Evaluation Period”). The Evaluation Period may be extended by Servier for duly justified reasons for an additional period not exceeding two (2) months. Unless earlier terminated pursuant to
Paragraph 11, the term of this Agreement shall commence on the Effective Date, and shall continue until four (4) months after the end of the Evaluation Period (the “Term”). 

 
 ***Confidential Treatment Requested 

	5.	Costs and Expenses. Servier and Celladon shall bear their own costs and expenses with respect to this Agreement (including, for the avoidance of doubt, in relation to the performance of the activities for which
they are responsible pursuant to Attachment 1). 

  

	6.	Exclusivity. In consideration of Servier’s agreement to disclose the Results to Celladon and Servier’s assignment to Celladon of all right, title and interest in and to all Compound Inventions at no
cost to Celladon pursuant to Section 8, Celladon agrees, during the Term (subject to extension as set forth below in this Section 6), to negotiate exclusively with Servier regarding the grant to Servier of an exclusive license with respect
to Compounds and Products in the Field in the Territory, and not to institute or conduct negotiations with any person, company or entity other than Servier regarding the license, sale or grant of other rights to such third party with respect to
Compounds and Products, whether in or outside of the Field, in the Territory (such agreement to negotiate exclusively with Servier, “Exclusivity”). At any time during the Term, Servier may notify Celladon in writing that Servier
wishes to negotiate for an exclusive, royalty-bearing license under the Licensed IP Rights, to make, have made, use, sell, have sold, offer for sale, and import Compounds and Products in the Field in the Territory, on the terms and conditions set
forth in Attachment 2 and other commercially reasonable terms and conditions to be negotiated in good faith by the Parties (capitalized terms used but not otherwise defined in this Agreement shall have the meanings provided in Attachment 2). Upon
Servier’s delivery of such written notice (the “Negotiation Notice”) to Celladon during the Term, (i) the Parties shall negotiate in good faith for up to [...***...] days (or such longer period as may be mutually agreed by
the Parties in writing) after such delivery of the Negotiation Notice (the “Negotiation Period”) a definitive license and research collaboration agreement (the “Collaboration and License Agreement”) containing the
terms and conditions set forth in Attachment 2 and other commercially reasonable provisions customarily included in license agreements relating to novel compounds for pharmaceutical applications, (ii) Exclusivity shall automatically be extended
until expiration of the Negotiation Period, and (iii) the Parties shall use commercially reasonable efforts to execute the Collaboration and License Agreement prior to expiration of the Negotiation Period. For clarity, Celladon shall at all
times be free to negotiate with, and grant any license, option or other right to, any third party with respect to Compounds and Products outside of the Territory, and nothing contained in this Agreement shall be construed to prohibit Celladon from
contracting with third party service providers for research, development or manufacturing services with respect to Compounds. In the event that Servier delivers the Negotiation Notice prior to expiration of the Term but the Parties, despite good
faith negotiations, have not executed the Collaboration and License Agreement prior to expiration of the Negotiation Period, then Celladon shall be free to negotiate with third parties regarding, and to grant to any third party, any license or other
right to develop and commercialize Compounds and Products in the Territory; provided, however, that for a period of [...***...] months after expiration of the Negotiation Period, Celladon shall not grant any third party any license or other
right to develop Compounds and Products in the Territory on principal financial terms that are more favorable to such third party than the principal financial terms in Attachment 2 are to Servier, without first offering to grant Servier such license
on such more favorable principal financial terms for a period of at least [...***...] days. 

  

	7.	Use of Materials. 

  

	 	(a)	Servier agrees that (i) Servier will use the Materials solely for the purpose of the Evaluation; (ii) the Materials will not be used on human subjects; (iii) the Materials will be used on animals in
compliance with all applicable laws, rules, regulations and other standards applicable to animal research and experimentation; and (iv) Servier shall not modify or create derivatives of the Materials or attempt to reverse engineer, deconstruct
or in any way determine the structure or composition of the Materials. 

  

	 	(b)	Celladon represents and warrants that it owns the Materials and that it has the right to provide Servier the Materials for Servier’s use as contemplated by this Agreement. 

 

	8.	Inventions and Results. 

  

	 	(a)	It is recognized and understood that the existing and/or already conceived respective inventions, discoveries and technologies of Servier and Celladon and intellectual property rights therein, are 

 
 ***Confidential Treatment Requested 

  
 2 

	 	
the separate property of the respective party and are not affected by this Agreement. Servier agrees to notify Celladon promptly in writing of any invention directed to a Compound, including,
without limitation, the composition of matter or formulation of, or any method of making or using, a Compound, whether in or outside of the Field, and any other improvement or enhancement to a Compound, in each case, whether or not patentable, that
is made, conceived, and/or reduced to practice under the Evaluation hereunder, regardless of inventorship (each, a “Compound Invention”). All Compound Inventions shall be owned solely by Celladon, and Servier hereby assigns to
Celladon all right, title and interest in and to all Compound Inventions, together with all patent and other intellectual property rights therein. Servier agrees promptly to disclose each Compound Invention to Celladon in writing and to execute such
documents and perform such other acts as Celladon may reasonably request to obtain, perfect and enforce such rights to the Compound Inventions and the assignment thereof. Servier also shall require that any employee, officer or consultant of Servier
or of any of its Affiliates or subcontractors that receives Materials shall agree to assign, and shall assign, to Servier (or, at Celladon’s request, directly to Celladon) any Compound Invention made by such employee, officer or consultant. All
information regarding Compound Inventions shall be Confidential Information of Celladon. If Servier delivers the Negotiation Notice during the Term and the parties execute a Collaboration and License Agreement, Celladon’s right, title and
interest in the Compound Inventions shall be licensed to Servier pursuant to the Collaboration and License Agreement. 

  

	 	(b)	Servier shall promptly disclose to Celladon in writing all results generated in the course of the Evaluation that are related to any Compound (“Results”). Results shall be subject to the provisions of
confidentiality set forth in this Agreement, subject to Section 8(c) below. Subject to Section 8(c) and Section 9 of this Agreement, neither Servier nor Celladon shall publish or otherwise disclose to any third parties any Results,
respectively, except that (i) if Servier has not delivered the Negotiation Notice to Celladon prior to expiration of the Term, or if Servier delivers the Negotiation Notice to Celladon prior to expiration of the Term but the parties fail to
enter into a Collaboration and License Agreement by the end of the Negotiation Period, Celladon may disclose the Results to third parties but Celladon shall not attribute any Results provided by Servier to Celladon as being provided by Servier and
(ii) Celladon may include the Results in any patent application claiming a Compound Invention. If Servier delivers the Negotiation Notice to Celladon prior to expiration of the Term and the parties execute a Collaboration and License Agreement,
Celladon’s right, title and interest in the Results shall be licensed to Servier pursuant to the Collaboration and License Agreement. 

  

	 	(c)	The Results shall be provided by Servier to Celladon “AS IS” without warranty of merchantability or fitness for any purpose and without any other warranty, expressed or implied and without any representation
or warranty that the use of the Results by Celladon will not infringe any patent of other proprietary right of any third party. Servier shall not be liable to Celladon for any loss, claim, or demand made by Celladon or made against Celladon by any
third party due to Celladon’s use of or reliance on the Results or any other information provided by Servier hereunder. 

  

	9.	Confidentiality. 

  

	 	(a)	“Confidential Information” shall mean all scientific, regulatory, marketing, financial, and commercial information or data, whether communicated in written, oral, graphic, electronic or visual form,
that is provided by one party (the “Disclosing Party”) to the other party (the “Receiving Party”) in connection with this Agreement; provided, however, that: 

(i) during the Term and the Negotiation Period (if any), all Results shall be deemed Confidential Information of both parties, and each party
shall be deemed both a Disclosing Party and a Receiving Party with respect thereto; 
 (ii) if Servier has not delivered the Negotiation
Notice to Celladon by the end of the Term, or if Servier delivers the Negotiation Notice to Celladon prior to expiration of the Term but the parties fail to enter into a Collaboration and License Agreement by the end of the Negotiation Period, all
Results shall be the Confidential Information of Celladon only, and Celladon shall be deemed the Disclosing Party and Servier the Receiving Party with respect thereto; and 

  
 3 

 (iii) all Compound Inventions shall at all times be deemed the Confidential Information of
Celladon only, and Celladon shall be deemed the Disclosing Party and Servier the Receiving Party with respect thereto. 
  

	 	    	Except as expressly set forth in this Agreement or as otherwise agreed in writing by the parties, the Receiving Party shall maintain the secrecy of the Disclosing Party’s Confidential Information, shall only use
the Disclosing Party’s Confidential Information as expressly authorized herein, and shall not disclose such Confidential Information to any third party without the prior written consent of the Disclosing Party, except that the Receiving Party
may share the Disclosing Party’s Confidential Information with those of its officers, directors, employees, consultants, agents and other representatives that have a need to know such information for the purposes expressly authorized by this
Agreement, have been advised by the Receiving Party of the Receiving Party’s obligations under this Agreement, and are bound by obligations of confidentiality and non-use at least as stringent as those set out herein. Servier may also disclose
the Confidential Information of Celladon to its Affiliates and subcontractors to the extent necessary for the conduct of the Evaluation, provided that each such Affiliate and subcontractor is bound by written agreement: (A) to obligations of
confidentiality and non-use at least as stringent as those set out herein; and (B) to assign all right, title and interest in and to all Compound Inventions and Results to Servier so that Servier may comply with its obligations under Paragraph
8 hereof. The Receiving Party shall use at least the same degree of care to protect the Disclosing Party’s Confidential Information as the Receiving Party would use to protect its own Confidential Information, but no less than reasonable care.
The parties’ obligations of confidentiality under this Paragraph 9 shall be in effect during the Term and for a period of seven (7) years from the date of termination of this Agreement. The failure of any officer, director, employee,
consultant or other representative of the Receiving Party to comply with the terms and conditions of this Agreement shall be considered a breach of this Agreement by the Receiving Party. 

 

	 	(b)	Confidential Information of the Disclosing Party shall not include information that the Receiving Party can demonstrate by competent evidence: (i) was already rightfully in its possession prior to receipt from the
Disclosing Party, as evidenced by its pre-existing written records (provided that the exception set forth in this clause (i) shall not apply to Compound Inventions or Results); or (ii) was in the
public domain at the time of its receipt from the Disclosing Party (or, in the case of Compound Inventions or Results, at the time of generation of such Results or Compound Inventions) or thereafter enters into the public domain through no act or
omission of the Receiving Party in breach of this Agreement; or (iii) is properly obtained by the Receiving Party from a third party with a valid right to disclose such information. Any and all Confidential Information of the Disclosing Party,
upon request by the Disclosing Party, shall be promptly returned by the Receiving Party, except that the Receiving Party may retain one copy of such information in confidential files, solely for record purposes. 

 

	 	(c)	Notwithstanding the preceding provisions of this Paragraph 8, the Receiving Party may disclose Confidential Information, without violating its obligations under this Agreement, to the extent the disclosure is required
by a valid order of a court or other governmental body of competent jurisdiction or is otherwise required by law or regulation, provided that the Receiving Party shall give reasonable prior written notice to the Disclosing Party of such
required disclosure and, at the Disclosing Party’s request and expense, shall cooperate with the Disclosing Party’s efforts to contest such requirement, to obtain a protective order requiring that the Confidential Information so disclosed
be used only for the purposes for which the order was issued or the law or regulation required, and/or to obtain other confidential treatment of such Confidential Information. 

 

	10.	Publicity/Use of Names. 

  

	 	(a)	No disclosure of the existence of, or the terms of, this Agreement may be made by either party, and no party shall use the name, trademark, trade name or logo of the other party or its employees in any publicity,
promotion, news release or disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other party, except as expressly set forth below in this Paragraph 10. 

  
 4 

	 	(b)	Servier agrees that Celladon shall have the right to issue an initial press release announcing the execution of this Agreement in substantially the form attached hereto as Attachment 3 on or after the Effective
Date. It is further acknowledged that each party may desire or be required by applicable laws, rules or regulations (including disclosure requirements of the U.S. Securities and Exchange Commission (“SEC”)) or the
requirements of any stock exchange on which securities issued by a party are traded, to issue subsequent press releases relating to this Agreement or activities hereunder. The parties agree that any such subsequent press releases shall be subject to
the other party’s prior consent and that the parties shall consult with each other reasonably and in good faith with respect to the text and timing of subsequent press releases prior to the issuance thereof, provided that a party may not
unreasonably withhold consent to such releases, and that either party may issue such press releases as it determines, based on advice of counsel, are reasonably necessary to comply with applicable laws, rules or regulations (including SEC disclosure
requirements) or with the requirements of any stock exchange on which securities issued by a party are traded. In the event of a required public announcement, to the extent practicable under the circumstances, the party making such announcement
shall use commercially reasonable efforts to provide the other party with a copy of the proposed text of such announcement sufficiently in advance of the scheduled release to afford such other party a reasonable opportunity to review and comment
upon the proposed text. Each party may make public statements regarding this Agreement in response to questions by the press, analysts, investors or those attending industry conferences or financial analyst calls, or issue press releases, so long as
any such public statement or press release is not inconsistent with prior public disclosures or public statements approved by the other party or otherwise permitted by this Paragraph 10 and does not reveal non-public information about the other
party. 

  

	 	(c)	The parties shall coordinate in advance with each other in connection with the filing of this Agreement (including redaction of certain provisions of this Agreement) with the SEC or other governmental agency or any
stock exchange on which securities issued by a party are traded, and each party shall use reasonable efforts to seek confidential treatment for the terms proposed to be redacted; provided that each party shall ultimately retain control over what
information to disclose to the SEC or any stock exchange or other governmental agency, as the case may be. Other than such obligation, neither party shall be obligated to consult with or obtain approval from the other party with respect to any
filings to the SEC or any stock exchange or other governmental agency. 

  

	11.	Termination. Servier may terminate this Agreement at any time with or without cause effective immediately upon written notice to Celladon. This Agreement will be terminated automatically at the end of the Term in
the event Servier has not delivered the Negotiation Notice to Celladon prior to expiration of the Term, or at the end of the Negotiation Period in the event Servier delivers the Negotiation Notice to Celladon prior to expiration of the Term. Upon
termination or expiration of this Agreement, Servier shall return or, at Celladon’s request, destroy all remaining Compounds. Neither expiration nor termination of this Agreement shall relieve either party of any obligation accruing prior to
such expiration or termination. 

  

	12.	Notices. Any notice required or provided for by the terms of this Agreement shall be in writing, addressed in accordance with this paragraph, and shall be delivered personally or sent by certified or registered
mail, return receipt requested, postage paid or by nationally-recognized express courier services providing evidence of delivery. The effective date of any notice shall be the date of first receipt by the receiving party. Notices shall be sent to
the address/addressee given below or to such other address/addressee as the party to whom notice is to be given may have provided to the other party in writing in accordance with this provision. 

 

					
	If to Servier:	 		  	Mrs Isabelle Tupinon-Mathieu
		 		  	INSTITUT DE RECHERCHES INTERNATIONALES SERVIER
		 		  	50, rue Carnot
		 		  	92284 Suresnes, France,
			
	With copy to:	 		  	 Mr Pascal Touchon
 SERVIER MONDE

50, rue Carnot,
 92284 Suresnes,
France,

  
 5 

					
	If to Celladon:	 		  	 Mr Fredrik Wiklund
 Celladon Corporation

12760 High Bluff Dr. Suite 240
 San Diego, CA 92130

USA

			
	With a copy to:	 		  	 Mrs Krisztina Zsebo
 12760 High Bluff
Dr. Suite 240
 San Diego, CA 92130
 USA

  

	13.	Entire Agreement. This Agreement, together with any attachments attached hereto and specifically referenced herein, constitutes the entire agreement between the parties with respect to the Evaluation, Exclusivity
and the negotiation of a Collaboration and License Agreement and supersedes and replaces any and all previous arrangements and understandings, whether oral or written, between the parties with respect to the Evaluation, Exclusivity and the
negotiation of a Collaboration and License Agreement. Any amendment or modification to this Agreement shall be of no effect unless made in a writing signed by an authorized representative of each party. 

 

	14.	Counterparts. This Agreement may be executed via electronic or facsimile forms or in two counterparts, facsimile and electronic transmission included, each of which shall be deemed an original and both of which
together shall constitute one and the same instrument. 

  

	15.	Survival. Paragraphs 8 through 13 and Paragraphs 15 and 16 shall survive termination or expiration of this Agreement. 

  

	16.	Governing Law. This Agreement, and all disputes and claims arising under this Agreement, will be interpreted and governed by the laws of England, without regard to its conflict of laws principles. In the event of
any controversy or dispute arising out of or relating to any provision of this Agreement, the construction, validity or breach thereof, such controversy or dispute shall be exclusively and finally settled by arbitration. Such arbitration shall be
held in Geneva, Switzerland, under the rules of the International Chamber of Commerce. The award of arbitration shall be final and binding upon both parties. The official language of the arbitration shall be English. The arbitration shall be decided
by three (3) arbitrators. The arbitrators shall not have the power to grant any award or remedy other than such awards or remedies that are available under English law. Notwithstanding the foregoing: (a) nothing contained in this Agreement
shall deny Celladon the right to seek injunctive or other equitable relief from a court of competent jurisdiction in the context of a bona fide emergency or prospective irreparable harm, and such an action may be filed before the arbitral
tribunal is formed and maintained notwithstanding any ongoing discussions between the parties or any ongoing arbitration proceeding; and (b) either party may bring an action in any court of competent jurisdiction to resolve disputes pertaining
to the validity, scope, enforceability, infringement, inventorship or ownership of intellectual property rights, and no such claim shall be subject to arbitration. 

  
 6 

 IN WITNESS WHEREOF, Celladon and Servier have executed this Agreement as of the date(s) set forth below. 

 

											
	LES LABORATOIRES SERVIER	 		  	CELLADON CORPORATION	 	
						
	BY:	 	 /s/ C. Bazantay
	 		  	BY:	  	 /s/ Krisztina Zsebo
	 	
	DATE:	 	20/2/2014	 		  	DATE:	  	Feb. 20, 2014	 	
	TITLE:	 	Proxy	 		  	TITLE:	  	President & CEO	 	

 INSTITUT DE RECHERCHES INTERNATIONALES SERVIER 
  

			
	BY:	 	 /s/ Isabelle Tupinon-Mathieu

	DATE:	 	20/2/2014
	TITLE:	 	Vice President Research and Development

  
 7 

 ATTACHMENT 1 

Evaluation2 

Purpose of the MTA 
 Test the Materials in a [...***...]
model of Type 2 Diabetes, in comparison with the [...***...] model as tested by Celladon. These results will be used to make a decision regarding the interest of a future collaboration with Celladon for the study of Compounds in the treatment of
Type 2 Diabetes. 
 Quantity of compound required for Evaluation 

[...***...] 
 In vitro tests

 [...***...] 
 In vivo/ ex vivo
tests 
 [...***...] 
  

	2	Please indicate quantities necessary to conduct the Evaluation hereunder 

  

***Confidential Treatment Requested 

  
 8 

 [...***...] 
  

***Confidential Treatment Requested 

  
 9 

 [...***...] 

Additional studies (if required) 
 [...***...] 

 
 ***Confidential Treatment Requested 

  
 10 

 [...***...] 

 
 ***Confidential Treatment Requested 

  
 11 

 ATTACHMENT 2 

Term Sheet for 
 the
Collaboration and License Agreement 
 Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to them in the
Agreement. 
  

			
	1. Parties	  	Servier and Celladon
		
	2. Scope	  	Collaboration and license agreement pursuant to which: (a) Servier and Celladon would collaborate to research and develop certain compounds; and (b) Servier would be granted certain licenses under the Licensed IP Rights and
Celladon’s interest in Joint Patents with respect to Selected Compounds and Products in the Field in the Territory (as such terms are defined below); each as more fully described below.
		
	3. Territory	  	Worldwide, excluding the United States of America and its territories and possessions.
		
	4. Product	  	Any pharmaceutical product that contains or comprises one or more Selected Compounds (as defined below).
		
	5. Compound	  	 Any small molecule compound that is a potent and selective SERCA modulator, and either:

 
 (a)    is owned or controlled
by Celladon on the date of the Collaboration and License Agreement or during the Research Collaboration Term, including, without limitation, CDN[...***...], CDN[...***...] and CDN[...***...] (together with related compounds as described in clause
(c) below, the “Celladon Compounds”); or
  

(b)    is generated, identified, conceived or reduced to practice by or on behalf of Celladon or
Servier, or jointly by or on behalf of Celladon and Servier, in the course of conducting Research Collaboration Plan activities during the Research Collaboration Term (together with related compounds as described in clause (c) below, the
“Collaboration Compounds”); or
  

(c)    is an analog, homolog, prodrug, metabolite, salt, ester, hydrate, solvate, polymorph,
isomer, enantiomer, free acid form, crystal form, free base form, racemate or derivative of any compound within the scope of the preceding clause (a) or clause (b).
  

For the purposes hereof, “Compounds” mean the Celladon Compounds and the Collaboration Compounds.

		
	6. Selected Compound	  	Any Compound that Servier selects for further development and commercialization in the Field in the Territory in accordance with paragraph 11 below, or any prodrug, metabolite, salt, ester, hydrate, solvate, polymorph, isomer,
enantiomer, free acid form, crystal form, free base form or racemate of such Compound.
		
	7. Celladon Research Technology	  	Patent rights and know-how owned or controlled by Celladon on the date of the Collaboration and License Agreement or during the Research Collaboration Term that are necessary or useful for the research, discovery, identification,
generation, screening, optimization or development of small molecule compounds that are potent and selective SERCA modulators, including, without limitation, Compounds and Celladon’s interest in Compound Inventions and Results.
		
	8. Licensed IP Rights	  	Patent rights and know-how owned or controlled by Celladon during the term of the Collaboration and License Agreement that are necessary or

 
 ***Confidential Treatment Requested 

  
 12 

			
		  	useful for the research, development, manufacture, use or sale of Selected Compounds and Products, including, without limitation, Celladon Research Technology directed to Selected Compounds.
		
	9. Field	  	 Type 2 diabetes and other metabolic diseases including, without limitation, lipid disorders, obesity, fatty liver diseases and diabetic
complications.
  
 Notwithstanding the foregoing, in the event Celladon wishes to develop
a Collaboration Compound with a third party in any field other than the field described above (the “Other Field”), Celladon would first discuss in good faith with Servier the terms of a possible arrangement between them with respect
to the development of such Collaboration Compound in the Other Field for a reasonable period to be set forth in the Collaboration and License Agreement, provided that Celladon shall not be obligated to enter into any such arrangement with Servier.
If an agreement is thereafter reached between Servier and Celladon, then:
  

•    the definition of “Field” would be extended to the Other Field only with
respect to such Collaboration Compound; and
  

•    if the Collaboration Compound was not previously selected by Servier for further
development pursuant to paragraph 11 below, such Collaboration Compound would be considered as selected by Servier for further development pursuant to paragraph 11 below upon execution of the agreement between Celladon and Servier, and would
therefore be treated as a “Selected Compound” for the purposes hereof.

		
	10. License Grants to Servier	  	 Celladon would grant to Servier:
  

(i)     an exclusive (except as to Celladon), royalty-bearing license, with the right to
sublicense solely to Servier’s affiliates, under the Celladon Research Technology and Celladon’s interest in Joint Patents, solely to perform the Research Collaboration Plan during the Research Collaboration Term (as such terms are defined
below); and
  
 (ii)    on a
Selected Compound-by-Selected Compound basis, effective upon Servier’s selection of each Selected Compound, an exclusive, royalty-bearing license, with the right to sublicense through multiple tiers of sublicense, under the Licensed IP Rights
and Celladon’s interest in Joint Patents, to research, develop, make, have made, use, sell, have sold, offer for sale and import such Selected Compound and Products containing or comprising such Selected Compound in the Field in the
Territory.
  
 Servier would covenant: (a) not to use Celladon Research Technology for
any purpose other than the performance of the Research Collaboration Plan and the research, development, manufacture, use and sale of Selected Compounds and Products; (b) not to initiate or have initiated any IND-enabling or GLP-compliant
preclinical study of a Compound without first selecting it as a Selected Compound; (c) not to conduct preclinical or clinical development of, or commercialize, in the Field any Compound that is not a Selected Compound; (d) not to research, develop
or commercialize any Compound (including, but not limited to, any Selected Compound) outside of the Field; and (e) not to cause or permit any of its affiliates or any third party to engage in any of the foregoing activities.

  
 13 

			
		
	11. Research Collaboration	  	 During a period to be agreed upon between the parties in the Collaboration and License Agreement (“Research Collaboration
Term”), the parties would collaborate, using the Celladon Research Technology, to screen, select and optimize small molecule compounds that are potent and selective SERCA modulators from Celladon’s proprietary chemical series and/or
any other compound library as may be agreed upon by the parties, to identify or generate Compounds for potential development in the Field, as more fully described in a written plan to be mutually agreed by the parties prior to signing of the
Collaboration and License Agreement (the “Research Collaboration Plan”).
  

Servier would have the right, at its option and upon written notice to Celladon, to select any Compound for further development and commercialization in the
Field in the Territory. Upon any such selection, the applicable Compound would become a Selected Compound.

		
	12. Research Collaboration Funding	  	Servier would fund the activities up to the agreed budget pursuant to the Research Collaboration Plan and would provide funding to Celladon for the performance of certain Research Collaboration Plan activities, as well as mutually
agreed upon external costs for such activities.
		
	13. Steering Committee	  	Servier and Celladon would establish a joint steering committee (JSC), on which they would have equal representation, to supervise the day-to-day Research Collaboration Plan activities. Disagreements would be resolved by escalation
to agreed executive officers of the parties. If no agreement is reached at such executive officers’ level, then Servier shall have the final say provided that no such decision shall create a new obligation on Celladon. The Collaboration and
License Agreement will also include other customary and reasonable limitations on Servier’s tie-breaking authority.
		
	14. License Grant-Back to Celladon	  	 Servier would grant to Celladon:
  

(i)     an exclusive (even as to Servier),
royalty-free, fully-paid, irrevocable and perpetual license, including the right to sublicense through multiple tiers of sublicense, under the Servier Technology and Servier’s interest in Joint Patents
(each as defined below), to research, develop, make, have made, use, sell, have sold, offer for sale and import Selected Compounds and Products in the Field outside of the Territory, provided however that Celladon’s right to use preclinical and
clinical efficacy data generated by Servier with respect to any Selected Compound and related Products would be subject to the reimbursement by Celladon of [...***...]% of the documented costs incurred by Servier in conducting the study(ies)
pursuant to which such data was generated. The reimbursement obligation would be limited to the development costs of the pre-clinical and clinical studies that Celladon or its third party sublicensee wishes to use in the context of the NDA
submission of the Products by or on behalf of Celladon or such third party licensee. Reimbursement would be due (i) no later than the date of NDA submission of the Products by or on behalf of Celladon, or (ii) if Celladon grants a third
party sublicensee license rights to develop and/or commercialize the Products in the Field outside of the Territory (the “US Third Party License”), absent any agreement between the parties pursuant to the following sentence,
promptly after Celladon notifies Servier on behalf of such third party sublicensee that such third party sublicensee wishes to use such data in an NDA, but in any event no later than NDA submission for the Products by such third party sublicensee.
Without prejudice to the foregoing, promptly following the execution of the US Third Party License, Celladon would provide written notice to Servier identifying the pre-clinical and clinical studies that the third party sublicensee wishes to use in
the context of the NDA submission of the Products

  
 ***Confidential Treatment Requested

  
 14 

					
		  	 by or on behalf of such third party licensee, following which Servier and Celladon and/or the third party sublicensee would enter
into good faith discussion for a period up to [...***...] months regarding (i) the timing for the reimbursement by the third party sublicensee of [...***...]% of the documented costs incurred by Servier in conducting such study(ies), and
(ii) if acceptable to the third party sublicensee, a possible collaboration with respect to the research and development of the Selected Compounds and the Products and the potential sharing of future costs and expenses in connection
mutually-agreed research and development activities;
  

(ii)    an exclusive (even as to Servier), royalty-free,
fully-paid, irrevocable and perpetual license, including the right to sublicense through multiple tiers of sublicense, under the Servier Technology and Servier’s interest in Joint Patents, to research, develop, make, have made, use, sell, have
sold, offer for sale and import Celladon Compounds (other than Selected Compounds) in the Field outside of the Territory; and
  

(iii)  an exclusive, worldwide, royalty-bearing, fully-paid, irrevocable and perpetual license, including
the right to sublicense through multiple tiers of sublicense, under the Servier Technology and Servier’s interest in Joint Patents, to research, develop, make, have made, use, sell, have sold, offer for sale and import Collaboration Compounds
(excluding Selected Compounds and Excluded Compounds) outside of the Field. Celladon would pay Servier (a) royalties at a rate of [...***...]% of the net sales of any product containing one or more of any such Collaboration Compounds (the
“Other Product”), and (b) the following milestone payments with respect to the first and second Other Products reaching such milestones provided, however, that if (i) the development of an Other Product for a particular
indication is abandoned after one or more of the milestone payments has been made and (ii) an Other Product containing a different Collaboration Compound (excluding Selected Compounds and Excluded Compounds) is developed for the same indication as
such dropped Other Product, then Celladon shall be entitled to credit any and all milestone payments previously made with respect to such dropped Other Product toward milestone payment obligations accruing with respect to the replacement Other
Product:

			
		  	Acceptance of the filing of a first Marketing Authorization Application for the first Other Product by the EMA:	  	[...***...] Euros
			
		  	Acceptance of the filing of a first Marketing Authorization Application for the second Other Product by the EMA:	  	[...***...] Euros
			
		  	First grant of a Marketing Authorization for the first Other Product by the European Commission following advice of the EMA:	  	[...***...] Euros
			
		  	First grant of a Marketing Authorization for the second Other Product by the European Commission following advice of the EMA:	  	[...***...] Euros
			
		  	Acceptance of the filing of a first New Drug Application by the FDA for the first Other Product:	  	[...***...] Euros
			
		  	Acceptance of the filing of a first New Drug Application by the FDA for the second Other Product:	  	[...***...] Euros

  

***Confidential Treatment Requested 

  
 15 

					
			
		  	Approval of the first New Drug Application for the first Other Product by the FDA:	  	[...***...] Euros
			
		  	Approval of the first New Drug Application for the second Other Product by the FDA:	  	[...***...] Euros
			
		  	Acceptance of the filing of a first Marketing Authorization Application for the first Other Product in Japan:	  	[...***...] Euros
			
		  	Acceptance of the filing of a first Marketing Authorization Application for the second Other Product in Japan:	  	[...***...] Euros
			
		  	First grant of a Marketing Authorization for the first Other Product in Japan:	  	[...***...] Euros
			
		  	First grant of a Marketing Authorization for the second Other Product in Japan:	  	[...***...] Euros
		
		  	 “Servier Technology” means: (a) all patents and patent applications owned or controlled by Servier that claim
the composition of matter or formulation of, or any method of making or using, any Compound or Product; and (b) all know-how, technology, trade secrets, information and data (including, but not limited to, pharmacological, toxicological and clinical
data and analytical and quality control data) that are necessary or useful for the manufacture, use or sale of any Compound or Product and that are generated by or on behalf of Servier either (i) in the course of conducting the Research
Collaboration Plan or (ii) in the course of developing or manufacturing any Selected Compound or Product. Any pre-clinical, clinical or other data disclosed to Celladon by Servier under the Collaboration and License Agreement would be provided
on an “as is” basis, without any warranty (express or implied) of any kind, and Servier would expressly disclaim all such warranties, provided that Servier would represent and warrant to Celladon that Servier has disclosed to Celladon all
safety data from IND-enabling preclinical studies and clinical trials conducted by or on behalf of Servier. Celladon and/or its sublicensees would accept all risk and liability in relation to the use of the data received from Servier and would
indemnify and hold harmless Servier from any third party’s claim(s) based upon such data.
  

“Joint Patents” means all patent applications and patents claiming Joint Inventions (defined below).

 
 “Excluded Compound” means any small molecule compound that is a potent
and selective SERCA modulator (excluding any Selected Compound) that:
  

(a)    either:
  

(i)     was owned or controlled by Servier prior to the date of the Collaboration and License
Agreement, other than as a result of conducting the Evaluation or the receipt or use of the Materials or any Confidential Information of Celladon;
  

(ii)    was acquired by Servier from a third party during the Research Collaboration Term; or

 
 (iii)  is an analog, homolog, prodrug,
metabolite, salt, ester, hydrate, solvate, polymorph, isomer, enantiomer, free acid form, crystal form, free base form, racemate or derivative of any compound within the scope of the preceding clause (i) or clause (ii), and was not generated,
identified, conceived or reduced to practice in whole or in part by or on behalf of Celladon; and

  

***Confidential Treatment Requested 

  
 16 

					
		  	 (b)    is not covered by, and does not use or incorporate, any Celladon Research
Technology.

		
	15. Development/Diligence Obligations	  	In developing and commercializing the Selected Compounds in the Territory, Servier would use the same level of commercial efforts as it would apply to its own programs of similar potential, taking into account the risks
of development, the commercial potential for the Product, its proprietary position and other relevant factors.
		
	16. Non-Compete	  	Celladon would not, directly or indirectly, engage in the development or commercialization of (i) Selected Compounds in the Territory (whether in or outside of the Field) and (ii) Collaboration Compounds in the Territory
and in the Field. Servier would not, directly or indirectly, engage in the development or commercialization of Selected Compounds outside of the Territory.
		
	17. Upfront Payment	  	Servier would pay to Celladon an upfront payment of [...***...] € within twenty (20) business days after the signature of the Collaboration and License Agreement.
		
	18. Annual License Fee	  	Servier would pay Celladon an Annual License Fee of [...***...] € on or before each anniversary of the signature of the Collaboration and License Agreement.
		
	19. Milestones Payments:	  	In addition, Servier would pay to Celladon, as and when due, the following payments with respect to the first and second Products (to the extent that such second Product is developed in indications within the Field other
than those of the first Product) reaching the milestones below (collectively, the “Milestones”); provided, however, that if (i) development of a Product for a particular indication is abandoned after one or more of the
Milestone payments has been made (a “Dropped Product”) and (ii) a Product containing a different Selected Compound is developed for the same indication as such Dropped Product (a “Replacement Product”), then Servier
shall be entitled to credit any and all Milestone payments previously made with respect to such Dropped Product toward Milestone payment obligations accruing with respect to the Replacement Product.
			
		  	IND Filing of the first Product:	  	[...***...] Euros
			
		  	First dosing of the first Product (or matched placebo or comparator drug) in the first Phase II:	  	[...***...] Euros
			
		  	First dosing of the first Product (or matched placebo or comparator drug) in the first Phase III:	  	[...***...] Euros
			
		  	First dosing of the second Product (or matched placebo or comparator drug) in the first Phase III:	  	[...***...] Euros
			
		  	Acceptance of the filing of a first Marketing Authorization Application for the first Product by the EMA:	  	[...***...] Euros
			
		  	Acceptance of the filing of a first Marketing Authorization Application for the second Product by the EMA:	  	[...***...] Euros
			
		  	Acceptance of the filing of a first Marketing Authorization Application for the first Product in Japan:	  	[...***...] Euros

  

***Confidential Treatment Requested 

  
 17 

					
			
		  	Acceptance of the filing of a first Marketing Authorization Application for the second Product in Japan:	  	[...***...] Euros
			
		  	First grant of a Marketing Authorization for the first Product by the European Commission following advice of the EMA:	  	[...***...] Euros
			
		  	First grant of a Marketing Authorization for the second Product by the European Commission following advice of the EMA:	  	[...***...] Euros
			
		  	First grant of a Marketing Authorization for the first Product in Japan:	  	[...***...] Euros
			
		  	First grant of a Marketing Authorization for the second Product in Japan:	  	[...***...] Euros
		
	20. Royalties	  	 Servier would pay Celladon royalties at a rate of [...***...]% (the “Royalty Rate”) of the net sales of such
Product. Royalties will be payable, on a country-by-country and Product-by-Product basis, from the first bona fide commercial sale of a Product in a country until the later of the expiration of the last to expire valid claim of any patent or patent
application within the Licensed IP Rights or the Joint Patents covering the manufacture, use or sale of such Product in such country, or ten (10) years from the date of first bona fide commercial sale of such Product in such country (the
“Royalty Term”). Following the expiry of such Royalty Term for a Product in a country, Servier’s license with respect to such Product in such country shall become perpetual, fully paid up and royalty free.

 
 The Royalty Rate for a Product in a country would be reduced to [...***...]% during any
portion of the Royalty Term for such Product in such country when both: (a) such Product is not covered by at least one valid claim of a patent or patent application within the Licensed IP Rights or Joint Patents in such country; and (b) generic
competition with respect to such Product in such country has reached a specified market share (to be negotiated) in such country. In the event the Product contains or comprises one or more Collaboration Compounds as its sole API, then the Royalty
Rate would be reduced to [...***...]% of the net sales of such Product and the Milestones would be reduced by [...***...]%.

		
	21. Inventorship / Ownership of Inventions	  	Inventorship of any discovery or invention, whether or not patentable, that is made, generated, developed or discovered, in whole or in part, by a Party or jointly by the Parties in the course of conducting Research
Collaboration Plan activities, including all patent and other intellectual property rights in or to any such discovery or invention (each, an “Invention”), would be determined in accordance with applicable patent laws. A party would
own all Inventions made solely by one or more employees, consultants and contractors of such party. Inventions made jointly by one or more employees, consultants and contractors of Servier and one or more employees, consultants and contractors of
Celladon (“Joint Inventions”) would be owned jointly by Servier and Celladon.
		
	22. Termination	  	The Collaboration and License Agreement would include customary termination rights and obligations, including (a) by Servier for convenience with a sixty (60) days’ prior written notice and (b) by either party for
material breach by the other party, which breach is not cured, or a remediation plan in relation to such breach is not provided and subsequently complied with, within a specified period after notice from the non-breaching
party.

  

***Confidential Treatment Requested 

  
 18 

			
		
	23. Confidentiality	  	The parties would agree to keep the provisions of the Collaboration and License Agreement confidential to the fullest extent permitted by applicable law and the rules of any stock exchange on which the securities of either party are
traded.
		
	24. Customary Terms	  	The Collaboration and License Agreement would contain customary terms, including terms and conditions relating to payments; patent rights and related protection and prosecutions; auditing and review rights; confidentiality;
representations and warranties (including with respect to the Celladon Research Technology); indemnities; and other customary provisions.
		
	25. Governing Law / Dispute Resolution	  	This Agreement, and all disputes and claims arising under this Agreement, would be interpreted and governed by the laws of England, without regard to its conflict of laws principles. In the event of any controversy or dispute
arising out of or relating to any provision of the Collaboration and License Agreement, the construction, validity or breach thereof, such controversy or dispute would be exclusively and finally settled by arbitration. Such arbitration would be held
in Geneva, Switzerland, under the rules of the International Chamber of Commerce. The award of arbitration would be final and binding upon both parties. The official language of the arbitration would be English. The arbitration would be decided by
three (3) arbitrators. The arbitrators would not have the power to grant any award or remedy other than such awards or remedies that are available under English law. Notwithstanding the foregoing, each party would have the right to seek injunctive
or other equitable relief from a court of competent jurisdiction in the context of a bona fide emergency or prospective irreparable harm, and such an action may be filed before the arbitral tribunal is formed and maintained notwithstanding
any ongoing discussions between the parties or any ongoing arbitration proceeding. In addition, either party would have the right bring an action in any court of competent jurisdiction to resolve disputes pertaining to the validity, scope,
enforceability, infringement, inventorship or ownership of intellectual property rights, and no such claim would be subject to arbitration.

  
 19 

 ATTACHMENT 3 

Form of Celladon Press Release 

Celladon Announces Option Agreement with Servier

— Servier Receives Exclusive Option to Enter Into Worldwide, ex-U.S., Research Collaboration 

and License for Celladon’s Novel Small Molecule SERCA2b Modulators for the Treatment of 

Diabetes and Metabolic Diseases — 

SAN DIEGO, CA, February 24, 2014 – Celladon Corporation (NASDAQ: CLDN), a clinical-stage biotechnology company focused on developing novel
therapies by applying its leadership position in the field of SERCA enzymes, today announced that Celladon and Servier have entered into an option agreement for a potential worldwide ex-U.S. research collaboration and license agreement for the
discovery and development of novel SERCA2b modulators for the treatment of type 2 diabetes and other metabolic diseases. The collaboration would leverage Celladon’s novel compounds, proprietary assays, and screening technology for isolation of
small molecule modulators of SERCA enzymes. 
 Under the terms of the agreement, Celladon granted Servier an exclusive option to license the worldwide,
ex-U.S., rights to the small molecule program in the field of diabetes and other metabolic disorders for a certain period. Servier’s decision to exercise its option will be based upon the outcome of a series of pre-defined in vitro and in vivo
studies to be performed by the parties. In the event Servier exercises its option, Celladon would receive certain upfront, research support and milestone payments, as well as royalties on sales. Celladon and Servier would jointly support the
discovery effort, while Servier would be primarily responsible for all costs associated in and for its territory with a global development plan, as well as ex-U.S. regulatory approval and commercialization of any compound selected as a lead
candidate. Celladon would retain all U.S. rights to any compounds and lead candidates developed through this collaboration and license agreement. 

About Celladon’s Small Molecule Program targeting SERCA2b enzymes 

The focus of our small molecule research program relates to the SERCA2b isoform of SERCA enzymes. Specifically, these enzymes control calcium movement in the
endoplasmic reticulum (ER) in all human cells. SERCA2b enzyme levels become deficient when cells are stressed, and accumulate unfolded proteins in the ER, known as ER stress. There has been a proliferation of publications in scientific medical
literature supporting the important role of ER stress in many diseases and conditions, including heart failure, diabetes and neurodegenerative diseases. We believe we are the industry leader in isolating small molecule modulators of the SERCA2b
enzyme, which can correct underlying calcium dysregulation and ER stress. Our proprietary, novel, first-in-class, compounds have demonstrated activity in multiple preclinical models of diseases and conditions. 

About Celladon 
 We are a clinical-stage biotechnology
company applying our leadership position in the field of calcium dysregulation by targeting SERCA enzymes to develop novel therapies for diseases with tremendous unmet medical needs. Sarco/endoplasmic reticulum Ca2+-ATPase, or SERCA, enzymes are a
family of enzymes that play an integral part in the regulation of intra-cellular calcium in all human cells. Calcium dysregulation is implicated in a number of important and complex medical conditions and diseases, such as heart failure, which is a
clinical syndrome characterized by poor heart function, resulting in inadequate blood flow to meet the body’s metabolic needs, as well as diabetes and neurodegenerative diseases. Our therapeutic portfolio for diseases characterized by SERCA
enzyme deficiency includes both gene therapies and small molecule compounds. MYDICAR, our most advanced product candidate, uses gene therapy to target SERCA2a, which is an enzyme that becomes deficient in patients with heart failure. In addition, we
have identified a number of potential first-in-class compounds addressing novel targets in diabetes and neurodegenerative diseases with our small molecule platform of SERCA2b modulators. 

  
 20 

 Contact: 
 Fredrik
Wiklund 
 Vice President, Corporate Development and Investor Relations 

(858) 432-7215 
 fwiklund@celladon.net 

About Servier 
 Founded in 1954, Servier is the first
independent French pharmaceutical research company. Its development is based on relentless pursuit of innovation in the following therapeutic areas: cardiovascular diseases, metabolic diseases, neurologic diseases, psychiatric diseases, rheumatic
diseases, and oncology. 
 In 2013, the company reported revenue of €4.2 billion. 92% of Servier medicines are prescribed internationally. At least 25%
of revenue from Servier drugs is reinvested in R&D every year. Servier has a strong international presence in 140 countries and employs more than 21,000 people worldwide. The Servier Group contributed 35% to the 2013 French trade surplus in the
pharmaceutical sector. 
 More information is available at: www.servier.com 

For more information, please contact: 
 Servier Communication
Department 
 Phone: +33 (0)1 55 72 60 37 
 Email:
presse@servier.fr 
 Forward-Looking Statements 

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Servier’s exercise of its option to enter into a research collaboration and license agreement with Celladon, as well as
Celladon’s small molecule program generally. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking
statements are based upon Celladon’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such
forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of conducting product development activities and clinical trials and obtaining regulatory approval to
commercialize product candidates, as well as our reliance on third parties and the need to raise additional funding when needed in order to conduct our business. These and other risks and uncertainties are described more fully in Celladon’s
filings with the Securities and Exchange Commission, including without limitation its Registration Statement on Form S-1 that was originally filed with the Securities and Exchange Commission on October 10, 2013, and the amendments thereto. All
forward-looking statements contained in this press release speak only as of the date on which they were made. Celladon undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on
which they were made. 

  
 21EX-10.18

 Exhibit 10.18 

EMPLOYMENT AGREEMENT 

This Employment Agreement (“Agreement”) is between bluebird bio, Inc., a Delaware corporation (the “Company”), and
Jason F. Cole (the “Executive”) and is made effective as of February 3, 2014 (the “Effective Date”). 

WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms and conditions
contained herein. 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: 
 1. Employment. 

(a) Term. The term of this Agreement shall commence on or before February 28, 2014, on a date to be mutually agreed to by
Executive and the Company and shall continue until terminated in accordance with the provisions of Section 3 (the “Term”). The actual first day of Executive’s employment shall be referred to as the “Start Date”. 

(b) Position and Duties. During the Term, the Executive shall serve as the Senior Vice President and General Counsel of the Company,
and shall have supervision and control over and responsibility for the day-to-day business and affairs of the Company and shall have such other powers and duties as may
from time to time be prescribed by the Chairman of the Board of Directors of the Company (the “Board”), the Chief Executive Officer of the Company (the “CEO”) or other authorized executive, provided that such duties are
consistent with the Executive’s position or other positions that he may hold from time to time. The Executive shall report to the CEO. The Executive shall devote his full working time and efforts to the business and affairs of the Company.
Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the Board, or engage in religious, charitable or other community activities as long as such services and activities are disclosed to the Board
and do not materially interfere with the Executive’s performance of his duties to the Company as provided in this Agreement. 
 2.
Compensation and Related Matters. 
 (a) Base Salary. During the Term, the Executive’s initial annual base salary shall
be $315,000. The Executive’s base salary shall be redetermined annually by the Board or the Compensation Committee. The annual base salary in effect at any given time is referred to herein as “Base Salary.” The Base Salary shall be
payable in a manner that is consistent with the Company’s usual payroll practices for senior executives. 
 (b) Incentive
Compensation. During the Term, the Executive shall be eligible to receive cash incentive compensation as determined by the Board or the Compensation Committee from time to time. The Executive’s target annual incentive compensation shall be
thirty-five percent (35%) of his Base Salary. To earn incentive compensation, the Executive must be employed by the Company on the day such incentive compensation is paid. 

 (c) Signing Bonus. On or about the first payroll period following the Start Date, the
Company shall pay Executive a signing bonus of $35,000 (the “Signing Bonus”). If Executive resigns from employment with the Company without Good Reason or is terminated for Cause within one year of the Start Date, Executive will be
obligated to repay the Signing Bonus to the Employer within thirty days of Executive’s termination. 
 (d) Equity. The Executive
shall be awarded an option to purchase 100,000 shares of the Common Stock of the Company at an exercise price equal to the closing price of the Company’s common stock on the NASDAQ Global Select Market on the first trading day of the first
calendar month following the Executive’s date of hire and to be memorialized in an Incentive Stock Option Agreement pursuant to the Company’s 2013 Stock Option and Incentive Plan. 

(e) Expenses. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by him during the
Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its senior executive officers. 

(f) Other Benefits. During the Term, the Executive shall be eligible to participate in or receive benefits under the Company’s
employee benefit plans in effect from time to time, subject to the terms of such plans. 
 (g) Vacations. During the Term, the
Executive shall be entitled to accrue paid vacation in accordance with the Company’s applicable policy. 
 3. Termination.
During the Term, the Executive’s employment hereunder may be terminated without any breach of this Agreement under the following circumstances: 

(a) Death. The Executive’s employment hereunder shall terminate upon his death. 

(b) Disability. The Company may terminate the Executive’s employment if he is disabled and unable to perform the essential
functions of the Executive’s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period. If any question shall arise as to
whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive’s then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of
the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the Executive’s guardian has no reasonable objection as to whether the Executive is so disabled or how
long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue. The Executive shall cooperate with any reasonable request of the physician in connection with such
certification. If such question shall arise and the Executive shall fail to submit such certification, the Company’s determination of such issue shall be binding on the Executive. Nothing in this Section 3(b) shall be construed to waive
the Executive’s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. §2601 et seq. and the Americans with Disabilities Act, 42 U.S.C. §12101 et seq. 

  
 2 

 (c) Termination by Company for Cause. The Company may terminate the Executive’s
employment hereunder for Cause by a vote of the Board at a meeting of the Board called and held for such purpose. For purposes of this Agreement, “Cause” shall mean: (i) the Executive’s dishonest statements or acts with respect
to the Company, any affiliate of the Company or any of the Company’s current or prospective customers, suppliers, vendors or other third parties with which such entity does business; (ii) the Executive’s commission of a felony or any
misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) the Executive’s failure to perform his assigned duties to the reasonable satisfaction of the Company, which failure, if curable, continues, in the reasonable
judgment of the Company, after written notice given to the Executive by the Company; (iv) the Executive’s gross negligence, willful misconduct or insubordination with respect to the Company or any affiliate of the Company; or (v) the
Executive’s violation of any provision of any agreement(s) between the Executive and the Company relating to noncompetition, nondisclosure and/or assignment of inventions. 

(d) Termination Without Cause. The Company may terminate the Executive’s employment hereunder at any time without Cause. Any
termination by the Company of the Executive’s employment under this Agreement which does not constitute a termination for Cause under Section 3(c) and does not result from the death or disability of the Executive under Section 3(a) or
(b) shall be deemed a termination without Cause. 
 (e) Termination by the Executive. The Executive may terminate his employment
hereunder at any time for any reason, including but not limited to Good Reason. For purposes of this Agreement, “Good Reason” shall mean that the Executive has complied with the “Good Reason Process” (hereinafter defined)
following the occurrence of any of the following events without the Executive’s express written consent: (i) a material diminution in the Executive’s responsibilities, authority and function; (ii) a material reduction in the
Executive’s Base Salary except pursuant to a salary reduction program affecting substantially all of the employees of the Company, provided, that it does not adversely affect the Executive to a greater extent than other similarly situated
employees and, provided further, that any reduction in the Executive’s Base Salary of more than ten percent (10%) shall constitute Good Reason; (iii) a material change of more than 30 miles in the geographic location at which the
Executive must provide services to the Company (except for required travel on Company business to an extent substantially consistent with the Executive’s usual business travel obligations); or (iv) the material breach by the Company of the
Company’s equity incentive plan or the stock option agreement governing the stock option granted to the Executive in connection with his hire (as described in the Offer Letter) or any other material agreement between the Executive and the
Company, if any, concerning the terms and conditions of the Executive’s employment, benefits or compensation. “Good Reason Process” shall mean that (i) the Executive reasonably determines in good faith that a “Good
Reason” condition has occurred; (ii) the Executive notifies the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii) the Executive cooperates in good
faith with the Company’s efforts, for a period not less than 30 days following such notice (the “Cure Period”) to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and
(v) the Executive terminates his employment within 60 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred. 

  
 3 

 (f) Notice of Termination. Except for termination as specified in Section 3(a), any
termination of the Executive’s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a “Notice of
Termination” shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon. 
 (g) Date
of Termination. “Date of Termination” shall mean: (i) if the Executive’s employment is terminated by his death, the date of his death; (ii) if the Executive’s employment is terminated on account of disability under
Section 3(b) or by the Company for Cause under Section 3(c), the date on which Notice of Termination is given; (iii) if the Executive’s employment is terminated by the Company under Section 3(d), the date on which a Notice
of Termination is given; (iv) if the Executive’s employment is terminated by the Executive under Section 3(e) without Good Reason, 30 days after the date on which a Notice of Termination is given, and (v) if the Executive’s
employment is terminated by the Executive under Section 3(e) with Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, (A) in the event that the Executive gives a
Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement, and (B) in the event that the Company
terminates the Executive’s employment without Cause under Section 3(d), the Company may unilaterally accelerate the Date of Termination to any earlier effective date provided that the Company continues to pay the Executive the Base Salary
for the 30-day period immediately following the date on which a Notice of Termination is given to the Executive. 
 4. Compensation Upon
Termination. 
 (a) Termination Generally. If the Executive’s employment with the Company is terminated for any reason, the
Company shall pay or provide to the Executive (or to his authorized representative or estate) (i) any Base Salary earned through the Date of Termination, unpaid expense reimbursements (subject to, and in accordance with, Section 2(c) of
this Agreement) and unused vacation that accrued through the Date of Termination on or before the time required by law but in no event more than 30 days after the Executive’s Date of Termination; and (ii) any vested benefits the Executive
may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans (collectively, the “Accrued Benefit”).

 (b) Termination by the Company Without Cause or by the Executive with Good Reason. During the Term, if the Executive’s
employment is terminated by the Company without Cause as provided in Section 3(d), or the Executive terminates his employment for Good Reason as provided in Section 3(e), then the Company shall pay the Executive his Accrued Benefit. In
addition, subject to the Executive signing a separation agreement containing, among other provisions, a general release of claims in favor of the Company and related persons and entities, confidentiality, return of property and non-disparagement, in
a form and manner 

  
 4 

 
satisfactory to the Company (the “Separation Agreement and Release”) and the Separation Agreement and Release becoming fully effective, all within the time frame set forth in the
Separation Agreement and Release: 
 (i) the Company shall pay the Executive an amount equal to 0.75 times the
Executive’s Base Salary (the “Severance Amount”); and 
 (ii) if the Executive was participating in the
Company’s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for 9 months or the Executive’s COBRA health continuation
period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company; and 

(iii) the amounts payable under this Section 4(b) shall be paid out in substantially equal installments in accordance with
the Company’s payroll practice over 9 months commencing within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Severance Amount shall begin
to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each
payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). 

(iv) The receipt of any severance payments or benefits pursuant to Section 4 will be subject to Executive not violating
the Restrictive Covenant Agreement referenced in Section 7 of this Agreement and attached hereto as Exhibit A, the terms of which are hereby incorporated by reference. In the event Executive breaches the Restrictive Covenant Agreement, in
addition to all other legal and equitable remedies, the Company shall have the right to terminate or suspend all continuing payments and benefits to which Executive may otherwise be entitled pursuant to Section 4 without affecting the
Executive’s release or Executive’s obligations under the Separation Agreement and Release. 
 5. Change in Control Payment.
The provisions of this Section 5 set forth certain terms of an agreement reached between the Executive and the Company regarding the Executive’s rights and obligations upon the occurrence of a Change in Control of the Company. These
provisions are intended to assure and encourage in advance the Executive’s continued attention and dedication to his assigned duties and his objectivity during the pendency and after the occurrence of any such event. These provisions shall
apply in lieu of, and expressly supersede, the provisions of Section 4(b) regarding severance pay and benefits upon a termination of employment, if such termination of employment occurs within 12 months after the occurrence of the first event
constituting a Change in Control. These provisions shall terminate and be of no further force or effect beginning 12 months after the occurrence of a Change in Control. 

  
 5 

 (a) Change in Control. During the Term, if within 12 months after a Change in Control, the
Executive’s employment is terminated by the Company without Cause as provided in Section 3(d) or the Executive terminates his employment for Good Reason as provided in Section 3(e), then, subject to the signing of the Separation
Agreement and Release by the Executive and the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination, 

(i) the Company shall pay the Executive a lump sum in cash in an amount equal to 0.75 times the Executive’s current Base
Salary (or the Executive’s Base Salary in effect immediately prior to the Change in Control, if higher); and 
 (ii) if
the Executive was participating in the Company’s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for 9 months or the
Executive’s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed
by the Company; and 
 (iii) The amounts payable under this Section 5(a) shall be paid or commence to be paid within 60
days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payment shall be paid or commence to be paid in the second calendar year by the last day of such
60-day period. 
 (b) Additional Limitation. 

(i) Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or
distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the
Internal Revenue Code of 1986, as amended (the “Code”) and the applicable regulations thereunder (the “Severance Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, the following provisions
shall apply: 
 (A) If the Severance Payments, reduced by the sum of (1) the Excise Tax and (2) the total of the
federal, state, and local income and employment taxes payable by the Executive on the amount of the Severance Payments which are in excess of the Threshold Amount, are greater than or equal to the Threshold Amount, the Executive shall be entitled to
the full benefits payable under this Agreement. 
 (B) If the Threshold Amount is less than (x) the Severance Payments,
but greater than (y) the Severance Payments reduced by the sum of (1) the Excise Tax and (2) the total of the federal, state, and local income and employment taxes on the amount of the Severance Payments which are in excess of the
Threshold Amount, then the Severance Payments shall be reduced (but not 

  
 6 

 
below zero) to the extent necessary so that the sum of all Severance Payments shall not exceed the Threshold Amount. In such event, the Severance Payments shall be reduced in the following order:
(1) cash payments not subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits. To the extent any payment
is to be made over time (e.g., in installments, etc.), then the payments shall be reduced in reverse chronological order. 

(ii) For the purposes of this Section 5(b), “Threshold Amount” shall mean three times the Executive’s
“base amount” within the meaning of Section 280G(b)(3) of the Code and the regulations promulgated thereunder less one dollar ($1.00); and “Excise Tax” shall mean the excise tax imposed by Section 4999 of the Code, and
any interest or penalties incurred by the Executive with respect to such excise tax. 
 (iii) The determination as to which
of the alternative provisions of Section 5(b)(i) shall apply to the Executive shall be made by a nationally recognized accounting firm selected by the Company (the “Accounting Firm”), which shall provide detailed supporting
calculations both to the Company and the Executive within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. For purposes of determining which of the
alternative provisions of Section 5(b)(i) shall apply, the Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination
is to be made, and state and local income taxes at the highest marginal rates of individual taxation in the state and locality of the Executive’s residence on the Date of Termination, net of the maximum reduction in federal income taxes which
could be obtained from deduction of such state and local taxes. Any determination by the Accounting Firm shall be binding upon the Company and the Executive. 

(b) Definitions. For purposes of this Section 5, the following terms shall have the following meanings: 

“Change in Control” shall mean “Sale Event,” as such term is defined in the Company’s 2013 Stock Option and Incentive
Plan. 
 6. Section 409A. 

(a) Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive’s separation from service within the
meaning of Section 409A of the Code, the Company determines that the Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive
becomes entitled to under this Agreement on account of the Executive’s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as
a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after the Executive’s

  
 7 

 
separation from service, or (B) the Executive’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment
covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule. 

(b) All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by
the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable
year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other
taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. 

(c) To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under
Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive’s termination of employment, then such payments or benefits shall be payable only upon the Executive’s “separation from
service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h). 

(d) The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any
provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this
Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either
party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. 

(e) The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this
Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. 

7. Confidential Information, Noncompetition and Cooperation. The Executive agrees to terms of the Assignment of Invention,
Nondisclosure and Noncompetition Agreement (“Restrictive Covenant Agreement”) attached hereto as Exhibit A, the terms of which are hereby incorporated by reference as material terms of this Agreement. 

8. Consent to Jurisdiction. The parties hereby consent to the jurisdiction of the Superior Court of the Commonwealth of Massachusetts
and the United States District Court for 

  
 8 

 
the District of Massachusetts. Accordingly, with respect to any such court action, the Executive (a) submits to the personal jurisdiction of such courts; (b) consents to service of
process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process. 

9. Integration. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and
supersedes all prior agreements between the parties concerning such subject matter. 
 10. Withholding. All payments made by the
Company to the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law. 

11. Successor to the Executive. This Agreement shall inure to the benefit of and be enforceable by the Executive’s personal
representatives, executors, administrators, heirs, distributees, devisees and legatees. In the event of the Executive’s death after his termination of employment but prior to the completion by the Company of all payments due him under this
Agreement, the Company shall continue such payments to the Executive’s beneficiary designated in writing to the Company prior to his death (or to his estate, if the Executive fails to make such designation). 

12. Enforceability. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any
section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to
which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. 

13. Survival. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the
Executive’s employment to the extent necessary to effectuate the terms contained herein. 
 14. Waiver. No waiver of any
provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement,
shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. 
 15.
Notices. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or
certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board. 

16. Amendment. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized
representative of the Company. 

  
 9 

 17. Governing Law. This is a Massachusetts contract and shall be construed under and be
governed in all respects by the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws principles of such Commonwealth. With respect to any disputes concerning federal law, such disputes shall be determined in
accordance with the law as it would be interpreted and applied by the United States Court of Appeals for the First Circuit. 
 18.
Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. 

19. Successor to Company. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or
otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no succession had taken place. Failure of
the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession shall be a material breach of this Agreement. 

20. Gender Neutral. Wherever used herein, a pronoun in the masculine gender shall be considered as including the feminine gender unless
the context clearly indicates otherwise. 

  
 10 

 IN WITNESS WHEREOF, the parties have executed this Agreement effective on the date and year first
above written. 
  

			
	BLUEBIRD BIO, INC.
		
	By:	 	 /s/ Nick Leschly

	Its:	 	 Chief Executive Officer

	
	 /s/ Jason F. Cole

	Jason F. Cole

 [Signature Page to the Employment Agreement] 

 Exhibit A 

Restrictive Covenant Agreement 
  

 
 ASSIGNMENT OF INVENTION, NONDISCLOSURE 

AND NONCOMPETITION AGREEMENT 
 This
Agreement is made between bluebird bio, Inc., a Delaware corporation (hereinafter referred to collectively with its subsidiaries as “bluebird bio” or the “Company’’), and Jason Cole, an employee or consultant of the
Company (the “Service Provider”). 
 In consideration of the employment or engagement, or the continued employment or engagement, of the Service
Provider by the Company, the Company and the Service Provider agree as follows: 
  

	1.	Noncompetition; Nonsolicitation. 

 a. During the term of Service Provider’s
provision of services to the Company and for one year after the termination or cessation of such services for any reason or no reason (the “Restricted Period”), Service Provider will not (i) engage, directly or indirectly, as an
advisor or consultant to, or be employed by, any entity engaged or proposing to engage in any business which is directly or indirectly competitive with the business of the Company in the Field (as defined in Section 3 hereof) (each, a
“Restricted Activity”), (ii) participate directly or indirectly in the ownership or management of any entity engaged in a Restricted Activity, (iii) assist others in engaging in a Restricted Activity in the manner described in
clauses (i) or (ii) above, (iv) solicit, entice or induce any employee or consultant of bluebird bio to terminate his or her employment or consultancy or engage in a Restricted Activity, or (v) solicit, entice or induce any
vendor, customer or distributor of bluebird bio to terminate or materially diminish its relationship with bluebird bio. Notwithstanding the foregoing, Service Provider shall have the right to own, for investment purposes, not more than one percent
of the outstanding capital stock of a publicly held enterprise which competes with bluebird bio and nothing contained in this Section 1 shall prevent Service Provider from being employed by a university or nonprofit research institution. 

b. Service Provider acknowledges and agrees that, in the event he/she breaches any of the terms described in Section 1.a above, the
Restricted Period shall be tolled and shall not run during the time that Service Provider is in breach of such obligations; provided that, the Restricted Period shall begin to run again once Service Provider has ceased breaching the terms of
Section 1.a and is otherwise in compliance with his/her obligations described therein. 
 c. Service Provider further acknowledges and
agrees that (i) the types of employment which are prohibited by Section 1.a are narrow and reasonable in relation to the skills which represent Service Provider’s principal salable assets both to bluebird bio and to other prospective
employers, and (ii) the specific but broad geographical scope of the provisions of Section 1.a is reasonable, legitimate and fair to Service Provider in light of the nature of the Company’s business, the Company’s need to market
and sell its services and products in an appropriate manner and in light of the limited restrictions on the type of activity prohibited compared to the activities for which Service Provider is qualified to earn a livelihood. 

 

 
  

	2.	Confidential Information. 

 a. Service Provider acknowledges that bluebird bio would be
irreparably damaged if Service Provider’s confidential knowledge of the business of bluebird bio was disclosed to or utilized on behalf of others. Service Provider acknowledges that he or she has learned and will learn bluebird bio Proprietary
Information, as defined in Section 2.b. hereof, relating to the business to be conducted by bluebird bio and its subsidiaries and joint ventures and partnerships to which bluebird bio may be a party (together, the “bluebird
bioEntities”). Service Provider agrees that he or she will not, except in the normal and proper course of his or her employment or consultancy or as otherwise provided herein, disclose or use or enable anyone else to disclose or use, either
during the term of this Agreement or subsequent thereto, any such bluebird bio Proprietary Information without prior written approval of bluebird bio. 

b. For the purpose of this Agreement, “bluebird bio Proprietary Information” shall mean all information, ideas, concepts,
improvements, discoveries, and inventions that are both (i) disclosed or made known by bluebird bio to Service Provider, and (ii) identified as “proprietary” by bluebird bio to Service Provider (either orally or in writing) at
the time of such disclosure, including, but not limited to, the following types of information: corporate information, including contractual licensing arrangements, plans, strategies, tactics, policies, resolutions, patent applications, and any
litigation or negotiations; marketing information, including sales or product plans, strategies, tactics, methods, customers, prospects, or market research data; financial information, including cost and performance data, debt arrangements, equity
structure, investors and holdings; operational information that relates to the technology that bluebird bio has or dosires to develop or market, including trade secrets, secret formulae, control and inspection practices, manufacturing processes and
methods, suppliers and parts; technical information, including machinery or device designs, drawings, specifications, processes, procedures, scientific or statistical data, research and development information, scientific protocols, clinical data
and preclinical data; and personnel information, including personnel lists, resumes, personal data, organizational structure and performance evaluations. 

c. Service Provider agrees that all documents of any nature provided by bluebird bio to Service Provider and pertaining to activities of any
bluebird bio Entity or to any bluebird bio Proprietary Information, in his or her possession now or at any time during the term of this Agreement, including without limitation memoranda, notebooks, notes, data sheets, records and blueprints, are and
shall be the property of bluebird bio, and that they and all copies of them shall be surrendered to bluebird bio upon the earlier of request by bluebird bio or termination of this Agreement. 

d. Service Provider shall have none of the obligations set forth above with respect to bluebird bio Proprietary Information (i) that is
publicly known or becomes publicly known through no breach of this Agreement by Service Provider, (ii) that is generally or readily obtainable by the public, or within 

 

 
  

 
the scientific field, (iii) that is known by Service Provider prior to its disclosure to Service Provider by bluebird bio, as shown by Service Provider’s written records, (iv) that
Service Provider received from a source that had the legal right to disclose the information to Service Provider, or (v) that is required to be disclosed by law, government regulation or court order. 

 

	3.	Intellectual Property.  

 Service Provider hereby assigns and agrees to assign to
bluebird bio his or her entire right, title and interest in and to all inventions, improvements, modifications, know-how, processes, secrets and discoveries made, possessed, discovered or conceived by him or her during the period in which the
Service Provider has provided services to the Company (whether or not patentable, whether or not reduced to practice, whether or not made, possessed, discovered or conceived by him or her individually or jointly with any other person or persons,
whether made or conceived on or off bluebird bio’s premises, and whether made in or out of working hours), which shall specifically or generally relate to, be applicable to or concern (a) development of therapeutics utilizing ex vivo or in
vivo nucleic acid (e.g., gene) transfer utilizing viral vector or virus-based approaches (e.g., lentivirus), (b) methods of manufacturing viral vectors or genetically modified cells for the development of therapeutics,
(c) approaches to facilitate proper homing or engraftment of genetically modified cells and (d) any other project, field, or line of business in which bluebird bio is engaged (collectively, the “Field”), such Inventions and
benefits hereof to immediately become the sole and absolute property of bluebird bio. In the event that any portion of this assignment is prohibited by the terms of a funding agreement under which the work resulting in any Invention was performed or
the regulations of the institution where such work was performed (in the event such work was not performed by bluebird bio), Service Provider shall use his or her best efforts to obtain for bluebird bio a license or other consent to use such
information on the most advantageous terms that are available to bluebird bio. Service Provider agrees that, upon the request of bluebird bio and at the expense of bluebird bio, Service Provider will execute such further assignments, documents, and
other instruments as may be necessary or desirable fully and completely to assign all such Inventions to bluebird bio and to assist bluebird bio in applying for, obtaining, and enforcing patents or copyrights or other rights in the United States and
in any foreign country with respect to any Invention. Service Provider shall keep and maintain adequate and current written records of all Inventions, in the form of notes, sketches, drawings or as may be specified by bluebird bio, which records
shall be available to and remain the sole property of bluebird bio at all times. Service Provider acknowledges that bluebird bio from time to time may have agreements with other persons or with the United States Government, or agencies thereof,
which impose obligations or restrictions on bluebird bio regarding inventions made during the course of work under such agreements or regarding the confidential nature of such work. Service Provider agrees to be bound by all such obligations and
restrictions which are made known to Service Provider and to take all action necessary to discharge the obligations of bluebird bio under such agreements. 

 

 
  

	4.	Publication.  

 Anything to the contrary herein notwithstanding, Service Provider may
publish any bluebird bio Proprietary Information or information regarding Inventions, (as defined above) of a scientific (as opposed to business or corporate) nature generated in the Field by Service Provider, but must give bluebird bio a copy of
the information to be published at least 30 days before submitting such information to the proposed publisher thereof, to provide bluebird bio with time to ensure that desired patent or any other proprietary rights in such scientific information are
not forfeited by such publication. Service Provider will cooperate with patent counsel for bluebird bio in effecting the intent of this Section by providing a copy of the text of the proposed publication at the time it is submitted to a journal or
other publication for consideration and by supplying data and information needed to file any patent applications or other appropriate materials to protect such information. 
  

	5.	Trade Secrets of Others/Obligations to Others. 

 Service Provider represents that his
other performance of all the terms of this Agreement does not and will not breach any agreement to keep in confidence proprietary information, knowledge or data acquired by him or her in confidence or in trust prior to his or her engagement by
bluebird bio, and Service Provider agrees that he or she will not disclose to bluebird bio, or induce bluebird bio to use, any confidential or proprietary information or material belonging to any other person. Service Provider agrees that he or she
will not enter into any agreement, either written or oral, in conflict with his obligations under this Agreement. 
  

	6.	Survival 

 The terms of this Agreement and Service Provider’s obligations hereunder
shall survive any termination of the Services Provider’s employment, contractual or other business relationship with bluebird bio, irrespective of the reason or reasons for such termination. 

 

	7.	Agreement Enforceable Upon Material Job Change. 

 Service Provider acknowledges and
agrees that if he/she should transfer between or among any affiliates of bluebird bio, wherever situated, or be promoted, demoted, reassigned to functions other than Service Provider’s present functions, or have his/her job duties changed,
altered or modified in any way, all terms of this Agreement shall continue to apply with full force. 
  

	8.	Disclosure to Future Employers. 

 Service Provider agrees to provide, and the Company, in
its discretion, may provide, a copy of this Agreement to any business or enterprise which Service Provider may directly or indirectly own, manage, operate, finance, join, control or in which Service Provider may participate in the ownership,
management, operation, financing, or control, or with which Service Provider may be connected as an officer, director, employee, partner, principal, agent, representative, consultant or otherwise. 

 

 
  

	9.	Modification.  

 This Agreement may not be changed, modified, released, discharged,
abandoned, or otherwise amended, in whole or in part, except by an instrument in writing signed by Service Provider and bluebird bio. 
  

	10.	Entire Agreement.  

 This Agreement constitutes the entire agreement and understanding
between the parties hereto and supersedes any previous oral or written communications, representations, understandings, or agreements relating to the subject matter hereof. 
  

	11.	Successors and Assigns. 

 This Agreement shall be binding upon and inure to the benefit
of the parties hereto and their respective successors and assigns (including, in the case of Service Provider, his or her heirs, executors, administrators and other legal representatives). Neither party hereto may assign any of its rights or
obligations hereunder to any other person, except that bluebird bio may assign all of its rights and obligations under this Agreement to any person or entity controlled by, in control of, or under common control with, bluebird bio. 

 

	12.	Counterparts.  

 This Agreement may be signed in two counterparts, each of which shall be
deemed an original and both of which shall together constitute one agreement. 
  

	13.	Notices.  

 All notices, requests, consents and other communications required or
permitted hereunder shall be in writing and shall be hand delivered or mailed by first-class mail postage prepaid, addressed as follows: If to bluebird bio, at bluebird bio, Inc., 840 Memorial Drive, Cambridge, MA 02139, Attention: CEO, or to such
other address as may have been furnished to Service Provider by bluebird bio in writing as herein provided; or if to Service Provider, at the address set forth below his or her signature hereon, or to such other address as may have been furnished to
bluebird bio by Service Provider as herein provided in writing. Any notice or other communication so addressed and so mailed shall be deemed to have been given when mailed, and if hand delivered shall be deemed to have been given when delivered.

  

	14.	Applicable Law. 

 This Agreement shall be deemed to have been made in the Commonwealth of
Massachusetts, shall take effect as an instrument under seal within Massachusetts, and the validity, interpretation and 

 

 
  

 
performance of this Agreement shall be governed by, and construed in accordance with, the internal law of Massachusetts, without giving effect to conflict of law principles, and specifically
excluding any conflict or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The parties acknowledge that the last act necessary to render this
Agreement enforceable is its execution by the Company in Massachusetts, and that the Agreement shall be maintained in Massachusetts. 
  

	15.	Jurisdiction, Venue, Service of Process and Jury Trial Waiver. 

 Any legal action or
proceeding with respect to this Agreement must be brought in the courts of the Commonwealth of Massachusetts or in the United States District Court for the District of Massachusetts and shall be subject to the jurisdiction of such courts only. By
execution and delivery of this Agreement, each of the parties hereto accepts for itself and in respect of its property, generally and unconditionally, the exclusive jurisdiction of the aforesaid courts. Any action, demand, claim or counterclaim
arising under or relating to this Agreement will be resolved by a judge alone and each of the Company and the Service Provider waive any right to a jury trial thereof. 
  

	16.	Severability. 

 The parties intend this Agreement to be enforced as written. However,
(a) if any portion or provision of this Agreement is to any extent declared illegal or unenforceable by a duly-authorized court having jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in
circumstances other than those as to which it is so declared illegal or unenforceable, will not be affected thereby, and each portion and provision of this Agreement will be valid and enforceable to the fullest extent permitted by law, and
(b) if any provision, or part thereof, is held to be unenforceable because of the duration of such provision or the geographic area covered thereby, the court making such determination will have the power to reduce the duration and/or
geographic area of such provision, and/or to delete specific words and phrases (“blue-pencilling”), and in its reduced or blue-pencilled form such provision will then be enforceable and will be enforced. 

 

	17.	Use of Name or Affiliation. 

 bluebird bio shall not use Service Provider’s name or
affiliation, in publicity, advertising, or securities offering materials without the prior written approval of Service Provider, provided that such approval shall not be unreasonably withheld in cases in which bluebird bio is required by applicable
law to disclose Service Provider’s relationship with bluebird bio. 
  

	18.	No Employment or Engagement Rights. 

 This Agreement does not constitute an agreement of
employment or engagement or imply that Service Provider’s employment or engagement with the Company shall continue for any period of time. 

 

 
  

 THE SERVICE PROVIDER ACKNOWLEDGES THAT HE/SHE HAS CAREFULLY READ THIS ASSIGNMENT OF INVENTION, NONDISCLOSURE
AND NONCOMPETITION AGREEMENT AND UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT. 
  

			
	bluebird bio, INC.
		
	By:	 	 /s/ Nick Leschly

		
	Print Name:	 	Nick Leschly
		
	Title:	 	Chief Executive Officer
		
	Date:	 	 2/3/14

	
	 SERVICE PROVIDER

		
	By:	 	 /s/ Jason F. Cole

		
	Print Name:	 	Jason Cole
		
	Date:	 	 2/3/14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}]]